PMID- 29467909
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 3
DP  - 2018 Mar
TI  - Apoptosis-sensitizing activity of birinapant in head and neck squamous cell 
      carcinoma cell lines.
PG  - 4010-4016
LID - 10.3892/ol.2018.7783 [doi]
AB  - Inhibitor of apoptosis proteins, which are overexpressed in head and neck 
      squamous cell carcinoma (HNSCC), may cause therapeutic resistance. Using SMAC 
      mimetic compounds, including birinapant, to degrade and/or inhibit these proteins 
      and sensitize apoptosis may enhance therapies in HNSCC. Fas expression was 
      analyzed in nine HNSCC cell lines and one keratinocyte cell line via flow 
      cytometry. These cell lines were treated with Fas ligand-Fc (FasL) and 
      birinapant, a bivalent SMAC mimetic, in mono and combination therapies. 
      Cytotoxicity was measured using a crystal violet assay. Annexin V assay was 
      performed for detection of apoptosis. The treatment efficacy of mono and 
      combination therapies was statistically analyzed. Nonlinear regression analysis 
      was performed to determine the inhibitory concentration (IC(10)) of birinapant. 
      Fas expression was detected in each cell line tested. Mono treatment with FasL 
      revealed minor to no apoptotic effects in the majority of the cell lines. Crystal 
      violet and Annexin V staining revealed increased apoptosis rates for all cell 
      lines following incubation with birinapant in mono treatment. Combination 
      treatment with FasL and birinapant (IC(10)) revealed additional and synergistic 
      effects in eight out of the ten cell lines. To the best of our knowledge, the 
      present study provided the first evidence of the apoptosis-sensitizing activity 
      of combination treatment with FasL and birinapant in HNSCC cell lines.
FAU - Brands, Roman C
AU  - Brands RC
AD  - Department of Oral and Maxillofacial Plastic Surgery, University Hospital 
      Wurzburg, D-97070 Wurzburg, Germany.
AD  - Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, D-97080 
      Wurzburg, Germany.
FAU - Scheurer, Mario J J
AU  - Scheurer MJJ
AD  - Department of Oral and Maxillofacial Plastic Surgery, University Hospital 
      Wurzburg, D-97070 Wurzburg, Germany.
FAU - Hartmann, Stefan
AU  - Hartmann S
AD  - Department of Oral and Maxillofacial Plastic Surgery, University Hospital 
      Wurzburg, D-97070 Wurzburg, Germany.
AD  - Interdisciplinary Center for Clinical Research, University Hospital Wurzburg, 
      D-97070 Wurzburg, Germany.
FAU - Seher, Axel
AU  - Seher A
AD  - Department of Oral and Maxillofacial Plastic Surgery, University Hospital 
      Wurzburg, D-97070 Wurzburg, Germany.
FAU - Kubler, Alexander C
AU  - Kubler AC
AD  - Department of Oral and Maxillofacial Plastic Surgery, University Hospital 
      Wurzburg, D-97070 Wurzburg, Germany.
FAU - Muller-Richter, Urs D A
AU  - Muller-Richter UDA
AD  - Department of Oral and Maxillofacial Plastic Surgery, University Hospital 
      Wurzburg, D-97070 Wurzburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20180112
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5796371
OTO - NOTNLM
OT  - apoptosis
OT  - head and neck squamous cell carcinoma
OT  - inhibitor of apoptosis
OT  - second mitochondria-derived activator of caspase
EDAT- 2018/02/23 06:00
MHDA- 2018/02/23 06:01
PMCR- 2018/01/12
CRDT- 2018/02/23 06:00
PHST- 2017/07/24 00:00 [received]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2018/02/23 06:00 [entrez]
PHST- 2018/02/23 06:00 [pubmed]
PHST- 2018/02/23 06:01 [medline]
PHST- 2018/01/12 00:00 [pmc-release]
AID - OL-0-0-7783 [pii]
AID - 10.3892/ol.2018.7783 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Mar;15(3):4010-4016. doi: 10.3892/ol.2018.7783. Epub 2018 Jan 
      12.